An Open Label Randomized Phase II Study Comparing Azd2014 Versus Everolimus In Patients With Advanced Metastatic Renal Cancer And Progression On VEGF Targeted Therapy

The study is a randomised trial allowing us to quantify the benefit and potential for further development of AZD2014. Repeat Xrays (CT scans) will be used to assess if the new drug delays tumour growth. Patients will be closely followed up in clinic to ensure safety. A maximum of 122 patients will be recruited into this multi centre national trial. The primary goal of the study is to investigate if AZ2014 delays the time for cancer regrowth (time to progression) compared to everolimus. For details click here.